LXRX Stock Overview
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Lexicon Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.65 |
| 52 Week High | US$3.79 |
| 52 Week Low | US$0.92 |
| Beta | 1.28 |
| 1 Month Change | -27.63% |
| 3 Month Change | -16.67% |
| 1 Year Change | -39.78% |
| 3 Year Change | -64.13% |
| 5 Year Change | -76.79% |
| Change since IPO | -98.74% |
Recent News & Updates
Recent updates
Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset
Mar 12Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do
Jan 26Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
Aug 08
Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment?
Apr 25Does Lexicon Pharmaceuticals (NASDAQ:LXRX) Have A Healthy Balance Sheet?
Jan 04Lexicon Pharma: Key Regulatory Event In May 2023
Oct 01Lexicon announces FDA review of heart failure therapy
Jul 27Lexicon Pharmaceuticals: Encouraging Signs Of Efficacy In Pain, But Still Looking For A Clear Win
Jul 13Lexicon Pharmaceuticals up 9% on mid-stage study for diabetic neuropathy drug
Jun 29Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment?
Jun 15Lexicon: Beaten Down Stock, High Risk-Reward Situation Ahead
May 31Shareholder Returns
| LXRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.1% | 0.5% | -0.7% |
| 1Y | -39.8% | 1.2% | 22.8% |
Return vs Industry: LXRX underperformed the US Biotechs industry which returned 0.1% over the past year.
Return vs Market: LXRX underperformed the US Market which returned 22.3% over the past year.
Price Volatility
| LXRX volatility | |
|---|---|
| LXRX Average Weekly Movement | 16.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LXRX's share price has been volatile over the past 3 months.
Volatility Over Time: LXRX's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 285 | Lonnel Coats | www.lexpharma.com |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Lexicon Pharmaceuticals, Inc. Fundamentals Summary
| LXRX fundamental statistics | |
|---|---|
| Market cap | US$379.20m |
| Earnings (TTM) | -US$177.12m |
| Revenue (TTM) | US$1.20m |
337.5x
P/S Ratio-2.3x
P/E RatioIs LXRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LXRX income statement (TTM) | |
|---|---|
| Revenue | US$1.20m |
| Cost of Revenue | US$58.97m |
| Gross Profit | -US$57.77m |
| Other Expenses | US$119.35m |
| Earnings | -US$177.12m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -0.72 |
| Gross Margin | -4,798.01% |
| Net Profit Margin | -14,710.88% |
| Debt/Equity Ratio | 106.9% |
How did LXRX perform over the long term?
See historical performance and comparison